Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

Inclusion Criteria:

Histologically or cytologically confirmed stage II or stage III non-small cell lung cancer, or stage IV non-small cell lung cancer that will be treated with curative intent
Evaluated by a surgeon and deemed inoperable
Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as 10mm or greater with chest CT scan.
No active malignancy within the past 5 years, except for non-melanoma skin cancers or carcinoma in situ of the cervix
18 years or older
Life expectancy of greater then 6 months
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Normal organ and marrow function as outlined in the protocol
Forced expiratory volume (FEV1) of 1 L or greater OR 50% or greater of predicted

Exclusion Criteria:

Primary tumor size greater then 6cm
Prior history of thoracic radiotherapy
May not be receiving any other study agents
History of pulmonary fibrosis
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin or etoposide
Primary tumor < 1.5 cm beyond hilar lymphadenopathy (if any) and 1.5 cm from proximal bronchial tree, defined as the trachea, right and left mainstem bronchus, and lobar bronchi until the 1st lobar segment
Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant or breast feeding women
Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy
Patients who are planned to receive the following medication: granulocyte colony-stimulating factor (G-CSF), bevacizumab, cetuximab, cyclosporine, anti-tumor necrosis factor agents, amifostine.